Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04456998
Recruitment Status : Recruiting
First Posted : July 7, 2020
Last Update Posted : January 20, 2022
Sponsor:
Information provided by (Responsible Party):
Gossamer Bio Inc. ( GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. )

Brief Summary:
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.

Condition or disease Intervention/treatment Phase
Pulmonary Artery Hypertension Drug: GB002 (seralutinib) Drug: Placebo Device: Generic Dry Powder Inhaler Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Subjects, investigators, other site personnel, and Sponsor (and/or designee) personnel who are directly involved in the conduct of the study, collection of the data, and analysis of the final safety and efficacy results will remain blinded to treatment assignments until after the completion of the study and the database has been locked.
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Actual Study Start Date : December 14, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : February 2023


Arm Intervention/treatment
Experimental: GB002 (seralutinib)
GB002 (seralutinib) inhaled orally twice per day (BID) over 24 weeks
Drug: GB002 (seralutinib)
Capsule containing GB002 (seralutinib)

Device: Generic Dry Powder Inhaler
Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery

Placebo Comparator: Placebo
Placebo inhaled orally BID over 24 weeks
Drug: Placebo
Matching capsule containing placebo

Device: Generic Dry Powder Inhaler
Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery




Primary Outcome Measures :
  1. Change from Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) [ Time Frame: Baseline, 24 weeks ]
    Change in PVR using right heart catheterization (RHC)


Secondary Outcome Measures :
  1. Change From Baseline to Week 24 on the Six-Minute Walk Test (6MWT) [ Time Frame: Baseline, 24 weeks ]
    Change in distance achieved on the 6MWT (Δ6MWD)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A current diagnosis of symptomatic PAH classified by one of the following:

    1. Idiopathic PAH (IPAH) or heritable pulmonary arterial hypertension (HPAH).
    2. PAH associated with connective tissue disease (CTD-APAH).
    3. PAH associated with anorexigen or methamphetamine use.
    4. Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair.
  2. 6MWD ≥ 150 meters and ≤ 550 meters at screening.
  3. WHO FC II or III symptomatology.
  4. Treatment with standard of care PAH background therapies.
  5. Documentation of cardiac catheterization within the screening period that is consistent with the diagnosis of PAH and meeting all the following criteria, to be confirmed by a central hemodynamic core laboratory:

    1. Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg (at rest), AND
    2. PVR ≥ 400 dyne•sec/cm5, AND
    3. Pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure (LVEDP) ≤12 mm Hg if PVR ≥400 to <500 dyne∙sec/cm5 OR
    4. PCWP or LVEDP ≤15 mmHg if PVR ≥500 dyne∙sec/cm5
  6. Pulmonary function tests (PFTs) at screening with the following criteria met:

    1. Forced expiratory volume in 1 second (FEV1) divided by the forced vital capacity (FVC) ≥70%;
    2. Total lung capacity (TLC) or FVC ≥ 70% predicted

Exclusion Criteria:

  1. Evidence of chronic thromboembolic disease or acute pulmonary embolism as assessed by ventilation-perfusion (V/Q) scan, computed tomography (CT)-angiogram, or pulmonary angiogram prior to screening.
  2. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during screening visit after a period of rest.
  3. Systolic blood pressure < 90 mm Hg during screening and baseline visits.
  4. WHO Pulmonary Hypertension Group 2-5.
  5. Human immunodeficiency virus (HIV)-associated PAH.
  6. History of left-sided heart disease and/or clinically significant cardiac disease.
  7. Untreated severe obstructive sleep apnea.
  8. History of atrial septostomy within 180 days prior to screening.
  9. Pulmonary venous occlusive disease (PVOD).
  10. Subjects with a history of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Child-Pugh Class A or higher; or baseline ALT or AST > 2 x ULN or Total Bilirubin ≥ 2 x ULN.
  11. History of malignancy within 5 years prior to screening.
  12. History of a potentially life-threatening cardiac arrhythmia with an ongoing risk.
  13. Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration (eg; history intracranial hemorrhage).
  14. Chronic renal insufficiency as defined by an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 via Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) at screening or requires dialytic therapy or hemofiltration.
  15. Hemoglobin (Hgb) concentration < 8.5 g/dL at screening.
  16. Evidence of active HIV, Hepatitis B or Hepatitis C, or tuberculosis (TB) infections.
  17. Inhaled prostanoids; these drugs may be withdrawn ≥ 4 weeks prior to or at screening, if clinically indicated.
  18. Use of oral anticoagulants (ie, warfarin or NOAC) at randomization.
  19. Requirement of intravenous (IV) inotropes (ie, levosimendan, dopamine, dobutamine, milrinone, norepinephrine) other than an IV prostanoid within 4 weeks of screening.
  20. Prior participation in GB002 studies and/or prior treatment with GB002.
  21. Currently participating in or has participated in a study of an investigational agent or has used an investigational device for the treatment of PAH within 4 weeks prior to screening.
  22. Current use of inhaled tobacco and/or inhaled marijuana.
  23. Current alcohol use disorder as defined by DSM-5 and/or positive test for drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).
  24. Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or hypersensitivity to lactose who, in the opinion of the investigator, may experience severe symptoms following the ingestion of lactose.
  25. QTcF of > 480 msec recorded on a screening or baseline ECG or receiving concurrent treatment with medications that prolong QT interval.
  26. Have any other condition or reason that, in the opinion of the Investigator or Medical Monitor, would prohibit the subject from participating in the study.

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04456998


Contacts
Layout table for location contacts
Contact: GB002, Inc. 1-866-668-4083 ClinicalTrials@gossamerbio.com

Locations
Show Show 70 study locations
Sponsors and Collaborators
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Investigators
Layout table for investigator information
Study Director: Richard Aranda Gossamer Bio Inc.
Layout table for additonal information
Responsible Party: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
ClinicalTrials.gov Identifier: NCT04456998    
Other Study ID Numbers: GB002-2101
First Posted: July 7, 2020    Key Record Dates
Last Update Posted: January 20, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Gossamer Bio Inc. ( GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. ):
seralutinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Arterial Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases